

# 2025 Current Fiscal Year Report: Malaria Vaccine Development Program

## Scientific Advisory Committee

Report Run Date: 06/05/2025 08:08:40 PM

<b>1. Department or Agency</b>		<b>2. Fiscal Year</b>	
Agency for International Development		2025	
<b>3. Committee or Subcommittee</b>		<b>3b. GSA Committee No.</b>	
Malaria Vaccine Development Program Scientific Advisory Committee		1056	
<b>4. Is this New Fiscal Year?</b>	<b>5. Current Charter</b>	<b>6. Expected Renewal Date</b>	<b>7. Expected Term Date</b>
No	07/29/2024	07/29/2026	02/25/2025
<b>8a. Was Terminated During Fiscal Year?</b>	<b>8b. Specific Termination Authority</b>		<b>8c. Actual Term Date</b>
Yes			02/25/2025
<b>9. Agency Recommendation for Next Fiscal Year</b>	<b>10a. Legislation Req to Terminate?</b>		<b>10b. Legislation Pending?</b>
Terminate	No		Not Applicable
<b>11. Establishment Authority</b> Agency Authority			
<b>12. Specific Establishment Authority</b>	<b>13. Effective Date</b>	<b>14. Committee Type</b>	<b>14c. Presidential?</b>
Action Memorandum	08/06/1997	Continuing	No
<b>15. Description of Committee</b> Scientific Technical Program Advisory Board			
<b>16a. Total Number of Reports</b>	No Reports for this Fiscal Year		
<b>17a. Open</b>	<b>17b. Closed</b>	<b>17c. Partially Closed</b>	<b>Other Activities</b>
0	0	0	0
<b>17d. Total</b>			
0			
<b>Meetings and Dates</b>			
No Meetings			

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00
<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

The committee reviews malaria vaccine development progress and plans on a semi-annual or annual basis. Following an extensive review of data and progress presented by MVDP staff or collaborators, the committee deliberates and makes recommendations on specific approaches to malaria vaccine development, which are then incorporated into the plans as appropriate.

**20b. How does the Committee balance its membership?**

The committee includes members with experience in industry and academia, and with expertise in vaccine development, malariology, immunology, molecular biology, and clinical evaluation of vaccines. Both broad and specific technical advice is therefore available.

**20c. How frequent and relevant are the Committee Meetings?**

The meetings are held semi-annually or annually to provide the necessary oversight to ensure the continuing appropriate conduct of the program. The MVDP staff sets the agenda in consultation with the committee chairman and members and invites collaborators to present recent work. As such, the committee is presented with the most relevant and up-to-date information on which to make their recommendations.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The committee is necessary to provide the requisite transparency and credibility to the process. Also, the MVDP staff value the committee's broad experience in all fields of malaria vaccine development and rely on the committee members for assistance in planning program direction.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

Meetings may be closed or partially closed to protect information that would disclose confidential trade secrets or commercial property such as patentable material.

**21. Remarks**

## Designated Federal Officer

Susan Youll DFO

Committee Members	Start	End	Occupation	Member Designation
Casimiro, Danilo	08/27/2024	08/27/2028	Vice President and Global Head of External Scientific Affairs Sanofi Vaccines R&D	Special Government Employee (SGE) Member
Coelho, Camila	08/27/2024	08/27/2028	Principal Investigator, Center for Vaccine Research and Pandemic Preparedness, Department of Microbiology, Icahn School of Medicine at Mount Sinai	Special Government Employee (SGE) Member
Espeseth, Amy	08/27/2024	08/27/2028	Senior Vice President of Vaccines and Infectious Diseases, Sail Biomedicines	Special Government Employee (SGE) Member
Hall, B. Fenton	08/27/2024	08/27/2028	Chief of the Parasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases	Regular Government Employee (RGE) Member
Kapulu, Melissa	08/27/2024	08/27/2028	Principal Research Investigator, KEMRI-Wellcome Trust Research Programme	Special Government Employee (SGE) Member
Kester, Kent	08/27/2024	08/27/2028	Head of Vaccine Research and Development, Coalition for Epidemic Preparedness Innovations (CEPI)	Special Government Employee (SGE) Member
Klein, Daniel	08/27/2024	08/27/2026	Senior Director of Protein & Structural Chemistry, Merck Research Laboratories	Special Government Employee (SGE) Member

Laufer, Miriam	08/27/2024	08/27/2026	Professor of Pediatrics and Director, Malaria Research Program	Special Government Employee (SGE) Member
			Center for Vaccine Development and Global Health, University of Maryland School of Medicine	
Riley, Eleanor	08/27/2024	08/27/2028	Professor Emerita, Immunology and Infectious Disease, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh	Special Government Employee (SGE) Member
Stewart, V. Ann	08/27/2024	08/27/2028	Professor (Retired), Uniformed Services University of the Health Sciences	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 10**

## Narrative Description

**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

Improvements to health or safety	<input type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input type="checkbox"/>

## Outcome Comments

**What are the cost savings associated with this committee?**

Checked if Applies

- |                            |                                     |
|----------------------------|-------------------------------------|
| None                       | <input checked="" type="checkbox"/> |
| Unable to Determine        | <input type="checkbox"/>            |
| Under \$100,000            | <input type="checkbox"/>            |
| \$100,000 - \$500,000      | <input type="checkbox"/>            |
| \$500,001 - \$1,000,000    | <input type="checkbox"/>            |
| \$1,000,001 - \$5,000,000  | <input type="checkbox"/>            |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/>            |
| Over \$10,000,000          | <input type="checkbox"/>            |
| Cost Savings Other         | <input type="checkbox"/>            |

**Cost Savings Comments**

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

0

**Number of Recommendations Comments**

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

%

**% of Recommendations Fully Implemented Comments**

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

%

**% of Recommendations Partially Implemented Comments**

**Does the agency provide the committee with feedback regarding actions taken to**

**implement recommendations or advice offered?**

Yes ☐ No ☐ Not Applicable ☒

**Agency Feedback Comments**

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Action Comments**

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input type="checkbox"/>
Online Committee Web Site	<input type="checkbox"/>
Online GSA FACA Web Site	<input type="checkbox"/>
Publications	<input type="checkbox"/>
Other	<input type="checkbox"/>

**Access Comments**